Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity

Cited by papers we hold 14

• Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential · 2025
  No notice
• Methylation across the central dogma in health and diseases: new therapeutic strategies · 2023
  No notice
• Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets · 2023
  No notice
• Mechanisms of Polycomb group protein function in cancer · 2022
  No notice
• EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment · 2022
  No notice
• Epigenetic modulation of antitumor immunity for improved cancer immunotherapy · 2021
  No notice
• Type I and II Interferons in the Anti-Tumor Immune Response · 2021
  No notice
• Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker · 2020
  No notice
• Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms · 2020
  No notice
• Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects · 2020
  No notice
• EZH2: a novel target for cancer treatment · 2020
  No notice
• HIF-2α is indispensable for regulatory T cell function · 2020
  No notice
• An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer · 2019
  No notice
• α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.